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Background:  4CMenB  (Bexsero),  a  vaccine  developed  against  invasive  meningococcal  disease  caused  by
capsular  group  B strains  (MenB),  was  recently  licensed  for  use  by  the  European  Medicines  Agency.  Assess-
ment  of  4CMenB  strain  coverage  in  speciﬁc  epidemiologic  settings  is  of  primary  importance  to  predict
vaccination  impact  on the  burden  of  disease.  The  Meningococcal  Antigen  Typing  System  (MATS)  was
developed  to predict  4CMenB  strain  coverage,  using  serum  bactericidal  antibody  assay  with  human
complement  (hSBA)  data  from  a diverse  panel  of  strains  not  representative  of  any  speciﬁc  epidemiology.
Objective:  To  experimentally  validate  the  accuracy  of  MATS-based  predictions  against  strains  represen-
tative  of  a  speciﬁc  epidemiologic  setting.
Methods and  results:  We  used  a  stratiﬁed  sampling  method  to  identify  a  representative  sample  from  all
MenB  disease  isolates  collected  from  England  and  Wales  in  2007–2008,  tested  the  strains  in  the  hSBAtratiﬁed proportional sampling assay  with  pooled  sera  from  infant  and  adolescent  vaccinees,  and  compared  these  results  with  MATS.
MATS  predictions  and  hSBA  results  were  signiﬁcantly  associated  (P = 0.022).  MATS  predicted  coverage  of
70%  (95%  CI,  55–85%)  was  largely  conﬁrmed  by  88%  killing  in the  hSBA  (95%  CI, 72–95%). MATS  had  78%
accuracy  and  96%  positive  predictive  value  against  hSBA.
Conclusion: MATS  is a  conservative  predictor  of  strain  coverage  by the  4CMenB  vaccine  in  infants  and
adolescents.Crown Cop
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. Introduction
Neisseria meningitidis capsular groups A, B, and C are respon-
ible for 90% of invasive meningococcal disease (IMD) [1], with
he remainder accounted for chieﬂy by groups Y, W,  and X [2].
lthough effective vaccines against capsular groups A, C, W,  and
 are available, the structural similarity of the capsular group
 polysaccharide to that of a constitutively expressed human
etal molecule has precluded the development of polysaccha-
ide vaccines against capsular group B meningococci (MenB) [3].
 genome-based approach, reverse vaccinology, was applied to
evelop a recombinant protein-based vaccine named 4CMenB,
ecently approved for use by the European Medicines Agency [4].
CMenB contains 4 main components: Neisserial adhesin A (NadA)
5,6], Neisserial heparin binding antigen (NHBA) [7], factor H bind-
ng protein (fHbp) [8,9], and porin A (PorA, presented as part of
n outer membrane vesicle [OMV] derived from strain NZ98/254)
10,11].
Serologic markers have been used to determine efﬁcacy of gly-
oconjugate vaccines against IMD, which were licensed based on
mmunogenicity and safety data in the absence of formal efﬁcacy
tudies [12]. The serum bactericidal antibody (SBA, or, when using
uman complement, hSBA) assay is an accepted surrogate of pro-
ection [13] used to determine the ability of serum antibody to lyse
 speciﬁc meningococcal strain. Because of diversity in sequence
nd expression level of the surface proteins used in 4CMenB,
etermining vaccine strain coverage could require performing the
SBA against many diverse N. meningitidis strains endemic to each
eographic region [14]. This approach is labor intensive, time con-
uming, and ethically unfeasible in infants, owing to the limited
olume of serum that can be collected.
To address this issue, the Meningococcal Antigen Typing Sys-
em (MATS) [15] combines conventional genotyping for PorA
ith a specialized sandwich enzyme-linked immunosorbent assay
ELISA) that quantiﬁes the relative expression and cross-reactivity
f antigenic variants by vaccine-induced antibody. The MATS ELISA
eadout is a relative potency (RP) against fHbp, NadA, and NHBA on
ndividual strains. To mitigate the need to perform hSBA on large
anels of isolates, the MATS method established the positive bac-
ericidal threshold (PBT), a minimum level of RP for fHbp, NadA,
nd NHBA, which predicts whether a given MenB isolate would be
usceptible to killing in the hSBA assay by 4CMenB-induced anti-
odies [15]. PBTs were derived by comparing MATS RPs and hSBA
iters from pooled postvaccination sera against a panel of 57 MenB
isease-causing isolates, covering a broad range of non-endemic
ultilocus sequence typing (MLST) and antigen genotypes from
arying geographic regions [16].
Experimental validation of PBT predictions on disease strains
elevant for a speciﬁc epidemiology is crucial to conﬁrm that the
elationship between MATS and hSBA can be used to assess 4CMenB
train coverage, deﬁned as the proportion of IMD-causing isolates
usceptible to killing in the hSBA by postvaccination sera. The major
actor limiting extensive validation of PBT predictions is the practi-
ality of performing large numbers of hSBA assays using sera from
ndividuals immunized with 4CMenB. We  developed an approach
or selecting a sufﬁcient number of representative MenB clinical
solates which allows experimental validation of PBT coverage pre-
ictions by comparing MATS and hSBA results from pooled sera on
n epidemiologically relevant collection of disease-causing isolates
ndependent of the strain panel used originally to derive the PBT.
In  a recently published study [17], 1460 culture-conﬁrmed IMD
solates identiﬁed from 7 European countries were tested in MATS
o assess strain coverage of 4CMenB. The meningococcal isolates
rom England and Wales had the largest representation in that sam-
le, 535 isolates, with a predicted strain coverage of 73% (95% CI,
7–87%) [17]. In this report, we describe a stratiﬁed proportional(2013) 4968– 4974 4969
random sampling procedure that has been used to select a repre-
sentative panel of 40 MenB isolates from the overall panel of 535
England and Wales isolates. The selected isolates were tested to
experimentally validate the accuracy of MATS-based predictions
of vaccine strain coverage.
2.  Materials and methods
2.1.  Deﬁnition of MATS phenotype
Each of the 4 antigens tested in MATS can score positive (“+”;
RP > PBT or PorA = 1.4) or negative (“−”; RP ≤ PBT or PorA /=  1.4).
Combining 2 possible states (“+” and “−”) for 4 antigens, we obtain
24 = 16 MATS phenotypes (Table S1). For example, an isolate scoring
positive for fHbp (RP > PBT) and PorA (=1.4), but not for NHBA and
NadA, would be assigned the phenotype “fHbp+, NHBA−, NadA−,
PorA+”. The MATS phenotype “fHbp−, NHBA−, NadA−, PorA−”
represents isolates predicted to be not covered by 4CMenB (i.e.,
MATS−). The other 15 phenotypes represent strains predicted cov-
ered by ≥1 antigens (i.e., MATS+).
2.2. Deﬁnition of genotypic proﬁles
Sequence type (ST) and clonal complex (CC) deﬁned by MLST,
genotypes for the fHbp, nhba, nadA genes and the porA variable
region 2 (VR2) were assigned as previously described [17].
For  each isolate we concatenated CC: fHbp genotype/nhba geno-
type/nadA genotype/porA VR2 to generate a “complete genotypic
proﬁle.” We used genotypic properties to substratify isolates within
each MATS phenotype stratum. Because the genetic variant of an
antigen is relevant to the susceptibility of the strain to killing in
the hSBA only if a sufﬁcient amount of the antigen is expressed
by the strain, for each strain we  deﬁned a genotypic proﬁle by
removing the genotype of the antigen/antigens that were MATS
negative in the MATS proﬁle for that strain. For example, a strain
belonging to the MATS phenotype “fHbp+, NHBA+, NadA−, PorA−”
with complete genotypic proﬁle CC32:1.p1/3/1/16 was assigned
the genotypic proﬁle CC32:1.p1/3/−/−.
2.3. Description of overall panel of isolates from England and
Wales
The  535 MenB isolates collected from England and Wales by the
Health Protection Agency from July 2007 to June 2008 have been
previously characterized as part of a larger study [17]. Brieﬂy, 50%
and 23% of strains scored positive for ≥2 and 1 antigens, respec-
tively, for an overall predicted coverage of 73%. Of  these, 64% and
55% of strains were fHbp+ and NHBA+, respectively, and 20% were
matched for PorA+. Few strains achieved NadA RP values above the
PBT (NadA+, 0.6%) despite 16% of isolates having intact alleles for
NadA by gene sequence analysis. Of the 16 possible MATS pheno-
types, only 10 were observed (Table S1). The 6 most frequent MATS
phenotypes were “fHbp+, NHBA+, NadA−, PorA−” (30%); all anti-
gens negative (27%); “fHbp+, NHBA+, NadA−, PorA+” (16%); fHbp+
only (15%); NHBA+ only (7.9%); and “fHbp+, NHBA−, NadA−, PorA+”
(3.2%). Four other MATS phenotypes had negligible frequencies
(<1%).
2.4. Stratiﬁed proportional sampling to select a subset of 40
strains
We  adapted stratiﬁed sampling methods [18] to experimen-
tally validate the predictions of vaccine coverage provided by the
MATS/PBT approach. For logistical reasons a maximum of 40 strains
could be tested in the hSBA assay; the characteristics of interest of
the strain population to be sampled were (1) the MATS phenotype
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nd (2) the strain genotypic proﬁle. Because the genetic variant of
n antigen is relevant to the susceptibility of the strain to killing in
he hSBA only if a sufﬁcient amount of the antigen is expressed by
he strain, we adopted a 2-stage, hierarchical stratiﬁcation scheme.
As the ﬁrst stage of stratiﬁcation, strains were grouped in sub-
ets deﬁned by their MATS phenotype. The number ni of isolates to
e sampled for each of the i = 1, . . . ,6 most frequent MATS phen-
types (strata) was calculated as ni = 40/535 × Ni, where Ni was
he number of strains belonging to the i-th stratum in the overall
ngland and Wales epidemiologic strain panel (Table S1).
Within  each stratum deﬁned by MATS phenotype, strains were
urther grouped into substrata deﬁned by their genotypic proﬁle,
onsidering only the genotypes of antigens positive in MATS for
hat particular stratum. The number nij of strains to be sampled in
he j-th substratum of the i-th stratum was calculated, as for the
rimary strata, proportionally to the size of the substrata (Table
2).
Within each of the stratiﬁcations deﬁned by these 2 criteria,
trains were sampled at random. Finally, 3 isolates belonging to
he “fHbp+, NHBA+, NadA−, PorA+” stratum, substratum CC41/44,
Hbp 1.4, NHBA 2, NadA−, PorA 1.4 were replaced with 3 equivalent
nvasive England and Wales isolates from 2009 and 2011 because
f the unavailability of the bacterial culture.
.5. Human serum samples
Healthy  human volunteers were immunized under informed
onsent. The 4CMenB vaccine contained 50 g each of GNA2091-
Hbp, NHBA-GNA1030, and NadA and 25 g of outer membrane
esicles from the strain NZ98/254 which were adsorbed to alu-
inum hydroxide. Serum samples before and after immunization
ere obtained from the following clinical trials.
Study 1 was a phase 2b/3 clinical trial conducted in healthy ado-
escents, aged 11–17 years [19]. Two pooled sera preparations were
erived from 13 subjects (1) before vaccination and (2) 30 days
fter the second dose of 4CMenB vaccine, administered 2 months
fter the ﬁrst dose. In the clinical trial, positive pre-vaccination
iters were observed against 4 strains tested. To favor a proper
ssessment of vaccine effect, the 13 sera used in the present study
ere randomly selected among the sub-set of subjects whose pre-
accination sera had shown negative hSBA titers in the clinical trial.
Study 2 was a phase 2b clinical study in which 4CMenB was
dministered to infants at 2, 4, and 6 months of age or 3, 5, and
 months of age [20]. Extensions of this clinical study investigated
 fourth (booster) dose at 12, 18, or 24 months of age. Pooled sera
ere derived from (1) 109 subjects at 13 months of age randomly
elected among those who  received only the routine vaccination
no 4CMenB, control group) and (2) from 69 subjects randomly
elected among those who received the primary series of 3 doses
f 4CMenB in the ﬁrst year of life, plus a booster in the second year
f life, 30 days after the booster dose was administered.
.6. Serum bactericidal antibody assay with human sera
Serum bactericidal antibody with human complement assays
ere performed as previously described [21] with minor modi-
cations. Human plasma obtained from volunteer donors under
nformed consent was selected for use as complement source with
 particular MenB strain only if it did not signiﬁcantly reduce the
umber of colony-forming units of that strain when added to the
ssay at a concentration of 50%. The ﬁnal assay mixture contained
5% human plasma. The activity of plasma complement was recon-
tituted by the addition of divalent cations immediately before use.
A strain was considered hSBA+, i.e. experimentally covered by
he 4CMenB vaccine, if the postvaccination hSBA titer was ≥1:8 (2013) 4968– 4974
and  ≥4-fold higher than the pre-immune titer (adolescents) or the
control group (infants) [15].
2.7. Statistical analyses
Statistical  analyses were performed using R, version 2.14.0
(www.r-project.org). Equivalence of genotypic and phenotypic
properties in the two panels (n = 535 isolates; n = 40 isolates) was
veriﬁed with proportion tests (R prop.test routine). Equivalence of
the medians for MATS RP distributions in the two panels was tested
for each antigen with the Wilcoxon test [22].
MATS-based predictions of 4CMenB strain coverage were com-
pared with hSBA results from the infant post-fourth-dose and
adolescent post-second-dose pools by classifying the 40 strains
tested with both assays into 2 × 2 contingency tables. Using MATS
+/− as predictor and hSBA +/− as outcome we deﬁned true positives
(TP), false positives (FP), true negatives (TN), and false nega-
tives (FN). Using values in the contingency tables, we  calculated
positive predictive value [TP/(TP + FP)], negative predictive value
[TN/(TN + FN)], and accuracy [(TP + TN)/(TP + FP + TN + FN)] [23] and
tested the statistical signiﬁcance of the MATS–hSBA association
with the Fisher exact test [24].
3. Results
3.1. Stratiﬁed proportional sampling identiﬁes an unbiased and
representative  40-strain sample of the original panel of strains
No  signiﬁcant bias was detected between the 40-strain subset
and the overall 535-strain panel comparing the frequency distri-
butions of the MATS antigen phenotypes (P = 0.999; Fig. 1A), the
distribution of MLST genotypes (P = 0.972; Fig. 1B), fHbp geno-
types (P = 0.576; Fig. 1C), and NHBA genotypes (P = 0.619; Fig. 1D).
Comparison of the MATS RP distributions for each antigen (fHbp,
NHBA, and NadA) also showed no bias between the 2 strain pan-
els (Wilcoxon text P = 0.828, 0.685, and 0.413 for fHbp, NHBA and
NadA, respectively; Fig. 2).
Vogel et al. [17] reported that MATS predicts 73% (95% CI,
57–87%) strain coverage of 4CMenB on the overall England and
Wales panel. The 4CMenB strain coverage predicted by MATS for
the selected 40-strain subset is 70% (95% CI, 55–85%), consistent
with coverage prediction on the overall England and Wales panel
(test for equality of 2 proportions, P = 0.830).
No signiﬁcant difference was observed between the 2 panels
for the empirical frequencies of MATS strata and genetic substrata
(P > 0.7 for all; Table 1), indicating that the selected sample of 40
strains is representative of the overall 535 strain panel.
3.2.  MATS predicts conservatively killing in the hSBA
Prevaccination (adolescents) or control (infants) hSBA titers
against the 40 strains tested were negative (<1:4), with the excep-
tion of 2 strains that had high prevaccination responses against the
adolescent sera (>1:32) with similar postvaccination titers (1:64)
and were therefore considered hSBA− in this age group (<4-fold
increase over prevaccination). The same strains had negative pre-
vaccination titers against infant sera (<1:4): 1 of 2 had a titer of
1:8 with post-fourth-dose infant sera and was considered hSBA+,
the other had 1:4 and was considered hSBA−. High and low pre-
vaccination titers with adolescent and infant serum, respectively,
suggest previous carriage of similar strains by some of the adoles-
cents composing the pool.All of the other strains with negative/low prevaccination hSBA
titers had postvaccination titers either negative and classiﬁed as
hSBA− (4 and 3 strains with infant and adolescent sera, respec-
tively), or positive (≥1:8 and ≥4-fold higher than the respective
G. Frosi et al. / Vaccine 31 (2013) 4968– 4974 4971
Fig. 1. Comparisons between distributions of (A) MATS antigen phenotypes, (B) MLST genotypes, (C) fHbp genotypes, and (D) NHBA genotypes in the England and Wales
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revaccination titer) and classiﬁed as hSBA+ (34 and 35 strains with
nfant and adolescent sera, respectively).
Overall, for both age groups, 35 of the 40 strains were classiﬁed
s hSBA+, for a measured strain coverage of 88% (95% CI, 72–95%)
Fig. 3). hSBA responses were highly concordant between the 2 age
roups, with all but 2 strains being positive or negative with both
nfant and adolescent sera.
MATS-based  predictions of coverage were largely conﬁrmed by
SBA results, with 27 TPs and 4 TNs (Table 2). One strain belonging
o the “fHbp+, NHBA−,NadA−, PorA−” stratum, CC18-fHbp1.147
ubstratum was predicted positive by MATS but not conﬁrmed by
SBA in either age group (1 FP). Eight strains predicted negative by
ATS, belonging to the CC269, CC41/44 or CC213, tested positive
n hSBA (8 FNs).
As  a predictor of pooled hSBA, MATS had a 96% positive predic-
ive value, a 33% negative predictive value, and an overall accuracy
f 78%, indicating that in this sample MATS underestimated strain
overage. Despite the underestimation observed, the association
etween the 2 assays was statistically signiﬁcant (Fisher exact
est, P = 0.022). MATS-predicted coverage was consistently lower
han coverage measured by hSBA using pooled sera from infants
nd adolescents, but the difference was not statistically signiﬁcant
P = 0.10).
ig. 2. Comparison of MATS relative potencies in the England and Wales complete and su
trains. fHbp = factor H binding protein; MATS = meningococcal antigen typing system; NATS = meningococcal antigen typing system; MLST = multilocus sequence typing;
Overall,  results conﬁrmed that, for infants and adolescents,
MATS is an accurate and conservative predictor of strain suscep-
tibility to killing in the hSBA.
4. Discussion
Initial comparisons of the relationship between MATS and SBA
relied on results from hSBA analysis of 57 MenB isolates using
pooled sera from infants who  had received 4 immunizations with
4CMenB [15]. Because the chosen isolates were not representative
of IMD  in any speciﬁc epidemiologic setting, conﬁrmation of the
relationship between MATS and hSBA assay using isolates that are
representative of those endemic to a particular geographic area
during a deﬁned period was  necessary.
Using a stratiﬁed proportional sampling method, we were able
to select a sample of 40 MenB isolates epidemiologically repre-
sentative of IMD  in England and Wales for the years 2007–2008.
MATS predicted 70% (95% CI, 55–85) coverage for this panel, and
hSBA from pooled infant and adolescent sera measured 88% (95%
CI, 72–95) coverage based on the accepted surrogate of protection.
Sixty-six percent of the strains predicted not covered by MATS were
killed in the hSBA assay (FNs) possibly owing to synergy of antibody
raised against multiple antigens, each of which was below the PBT.
bset strain panels. (A) fHbp, (B) NHBA, (C) NadA (all strains); Insert: NadA positive
adA = Neisserial adhesin A.
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Table  1
Comparison of MLST/genotype distribution in overall panel and selected subpanel.
Strata (MATS phenotype) Substrata (genotypic proﬁle) England and Wales
panel  (n, % of
stratum)
40  strains subpanel
(n,  % of stratum)
fHbp−, NHBA−, NadA−, PorA−
E&W  full set = 144 strains
E&W subset = 12 strains
CC269:−/−/−/− 48 (33.3) 5 (41.7)
CC213:−/−/−/− 43 (29.9) 5 (41.7)
CC41/44:−/−/−/− 11 (7.6) 2 (16.6)
Other  proﬁles (11) 42 (29.2) 0 (0.0)
fHbp+,  NHBA+, NadA−, PorA−
E&W full set = 160 strains
E&W subset = 12 strains
CC269: 1.p15/21/−/− 74 (46.3) 7 (58.4)
CC41/44:  1.p4/2/−/− 35 (21.9) 3 (25.0)
CC32:  1.p1/3/−/− 15 (9.4) 1 (8.3)
CC41/44:  1.p14/2/−/− 6 (3.8) 1 (8.3)
Other  proﬁles (27) 30 (18.8) 0 (0.0)
fHbp+,  NHBA+, NadA−, PorA+
E&W  full set = 84 strains
E&W subset = 7 strains
CC41/44: 1.p4/2−/+ 62 (75.0) 6 (85.7)
CC41/44:  1.p14/2−/+ 12 (14.3) 1 (14.3)
Other  proﬁles (9) 9 (10.7) 0 (0.0)
fHbp+,  NHBA−, NadA−, PorA−
E&W full set = 78 strains
E&W subset = 5 strains
CC269: 1.p13/−/−/− 14 (17.9) 1 (20.0)
CC32:  1.p1/−/−/− 14 (17.9) 2 (40.0)
CC269:  1.p15/−/−/− 10 (12.8) 1 (20.0)
CC18:  1.p147/−/−/− 8 (10.3) 1 (20.0)
Other  proﬁles (21) 32 (41.0) 0 (0.0)
fHbp−,  NHBA+, NadA−, PorA−
E&W full set = 42 strains
E&W subset = 3 strains
CC269:−/21/−/− 8 (19.0) 1 (33.3)
CC162:−/20/−/− 5 (11.9) 1 (33.3)
CC269:−/17/−/− 5 (11.9) 1 (33.4)
Other  proﬁles (17) 24 (57.1) 0 (0.0)
fHbp+,  NHBA−, NadA−, PorA+
E&W full set = 17 strains
E&W subset = 1 strain
CC41/44: 1.p4/−/−/+ 13 (75.5) 1 (100)
Other  proﬁles (3) 4 (23.5) 0 (0.0)
f ST = m
b
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bHbp = factor H binding protein; MATS = meningococcal antigen typing system; ML
inding antigen; PorA = porin A.
nly 1 of the 28 strains predicted positive by MATS was  resistant
o killing in the hSBA assay for a proportion of FPs lower than in the
7-strain panel (3% vs. 11%, respectively). This difference was not
urprising because the proportion of strains predicted covered by
2 antigens was  higher in the England and Wales panel than in the
7-strain panel (50% vs. 35%) and the rate of FPs has been shown to
e lower in such strains [15]. The high proportion of strains positive
n MATS for ≥2 antigens might also account for the similar killing
n hSBA observed for infants and adolescents, whereas previous
ig. 3. MATS yields conservative predictions of 4CMenB strain coverage as measured 
stimated according to the MATS interlaboratory standardization study [33] using the P
Is  were constructed on the basis of the binomial approximation (Clopper–Pearson m
ndpoint was post dose 4; for adolescents the endpoint was post dose 2. fHbp = factor H bi
ATS = meningococcal antigen typing system; NadA = Neisserial adhesin A; NHBA = Neis
actericidal antibody.ultilocus sequence typing; NadA = Neisserial adhesin A; NHBA = Neisserial heparin
studies  reported lower hSBA coverage in infants compared with
adolescents [15]. Overall, these effects might explain the smaller
value of strain coverage predicted by MATS compared with pooled
hSBA results and validate the rationale for a multicomponent vac-
cine.Comparison of MATS predictions with hSBA results for each
strain conﬁrmed a statistically signiﬁcant association between
the 2 assays with good accuracy and positive predictive power
demonstrating that, as recently suggested, MATS could be
by pooled hSBA with infant and adolescent sera. MATS coverage intervals were
BTs and a log-normal approximation based on overall assay reproducibility. hSBA
ethod). Results of the hSBA assay were tested with pooled sera. For infants the
nding protein; hSBA = serum bactericidal antibody assay with human complement;
serial heparin binding antigen; PBT = positive bactericidal threshold; SBA = serum
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Table 2
Contingency table for MATS coverage vs. hSBA coverage comparison.
MATS hSBAa
Positive Negative
Positive 27 1
Negative 8 4
hSBA, serum bactericidal antibody assay with human complement; MATS, meningo-
coccal antigen typing system; PBT, positive bactericidal threshold; PorA, porin A; RP,
relative potency.
a Pooled sera from infant vaccinees post fourth dose and adolescent vaccinees
post  second dose of the 4CMenB vaccine (same results for both age groups). MATS
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2005;12:970–6.ositive: RP > PBT for one or more antigens and/or PorA = P1.4. hSBA positive: pos-
immune titer ≥1:8 and ≥4-fold increase over preimmune.
sed as a relevant tool for post-implementation surveillance
25].
The complete set of 535 England and Wales strains from which
he 40-strain sample was selected is currently the largest panel
f invasive MenB strains isolated in a single country typed in
ATS [17,26–32]. The size of the panel and the similar predictions
f vaccine strain coverage in other epidemiologic panels stud-
ed support the relevance of the results obtained in this study to
he MATS-based predictions of 4CMenB strain coverage in other
ountries.
Lacking in these studies are hSBA data using sera from individ-
als; an impractical undertaking, especially among infants from
hom limited sample quantities are available. To complement the
esults seen here overcoming this limitation, the general relation-
hip between pooled and individual sera from different age groups
ay be investigated. Also, additional studies may  be conducted to
etermine the fewest number of isolates necessary to retain the
verall diversity in an epidemiologic panel of clinical isolates.
In  summary, results of the present study show that MATS pro-
ides accurate and conservative estimates of strain coverage by
he 4CMenB vaccine for a strain panel representative of IMD  in
 speciﬁc geographic setting and epidemiologic year. This further
llustrates the value of the MATS approach, which may  be tailored
or use with other pathogens with the potential of providing addi-
ional epidemiologic and efﬁcacy data geared toward optimizing
reatment.
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